COVID-19: IMI2 – Call 21
In our aspiration to contribute to the fight against COVID-19 with our science, technology and experts, we are actively engaging in ongoing joint projects. We have joined a fast track call initiated by the Innovative Medicines Initiative (IMI) of the European Union by contributing our ongoing COVID-19 projects. IMI has been created by the European Union to accelerate the development of new medical therapies by fostering collaboration between industry and academic research, which makes it an ideal platform to develop treatments against COVID-19.
Boehringer Ingelheim contributes to the consortium with its leading capabilities and expertise in small molecule and biopharmaceutical drug research, development and manufacturing.